Vanda Pharmaceuticals appoints chief commercial officer
Bob Repella joins US biopharmaceutical firm
Repella has more than 25 years of experience in the biotech/pharmaceutical industry, including senior-level leadership roles in global marketing, sales, new product development and commercial operations.
Prior to joining Vanda, he was senior vice president of Pharmaceutical Operations for the Americas at Cephalon.
Before this, Repella was executive vice president and general manager of the Biopharma Business Unit for Wyeth Pharmaceuticals.
Earlier in his career, Repella held positions with Johnson & Johnson's McNeil Pharmaceutical Division, Merck & Co and Eli Lilly.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions
New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date